HypErthermia as an Additional Treatment for the Biology and Experience of Depression
| 対象疾患 | Major Depressive Disorder |
|---|---|
| 相 | 該当なし |
| スポンサー | University of California, San Francisco |
| ステータス | 完了 |
| 参加者数 | 16 名 |
| 介入（薬剤） | Cognitive Behavioral Therapy (CBT), Whole-Body Hyperthermia (WBH) |
| 開始日 | 2021年10月11日 |
| 完了日 | 2023年3月1日 |
| 結果公開日 | 2024年6月12日 |
概要
This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or older with major depressive disorder (MDD).
Average Number of Planned WBH Sessions Completed
| Cognitive Behavioral Therapy (CBT) and 8 Sessions Whole-Body Hyperthermia (WBH) | 7.83 ± 0.41 Count of WBH Sessions |
|---|---|
| Cognitive Behavioral Therapy (CBT) and 4 Sessions Whole-Body Hyperthermia (WBH) | 3.20 ± 1.40 Count of WBH Sessions |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital